Last reviewed · How we verify

PTP-01 — Competitive Intelligence Brief

PTP-01 (PTP-01) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Protein tyrosine phosphatase inhibitor. Area: Oncology.

phase 3 Protein tyrosine phosphatase inhibitor Protein tyrosine phosphatase (PTP) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

PTP-01 (PTP-01) — University of Virginia. PTP-01 is a protein tyrosine phosphatase inhibitor that modulates immune cell signaling to enhance anti-tumor immunity.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
PTP-01 TARGET PTP-01 University of Virginia phase 3 Protein tyrosine phosphatase inhibitor Protein tyrosine phosphatase (PTP)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Protein tyrosine phosphatase inhibitor class)

  1. University of Virginia · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). PTP-01 — Competitive Intelligence Brief. https://druglandscape.com/ci/ptp-01. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: